1. Home
  2. CNC vs GKOS Comparison

CNC vs GKOS Comparison

Compare CNC & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Centene Corporation

CNC

Centene Corporation

HOLD

Current Price

$39.89

Market Cap

18.7B

Sector

Health Care

ML Signal

HOLD

Logo Glaukos Corporation

GKOS

Glaukos Corporation

HOLD

Current Price

$116.64

Market Cap

5.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CNC
GKOS
Founded
1984
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
18.7B
5.4B
IPO Year
2001
2015

Fundamental Metrics

Financial Performance
Metric
CNC
GKOS
Price
$39.89
$116.64
Analyst Decision
Hold
Strong Buy
Analyst Count
17
13
Target Price
$40.06
$126.38
AVG Volume (30 Days)
6.2M
793.3K
Earning Date
02-03-2026
10-29-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$167,680,000,000.00
$469,820,000.00
Revenue This Year
$32.54
$31.15
Revenue Next Year
$0.19
$24.15
P/E Ratio
N/A
N/A
Revenue Growth
14.57
30.38
52 Week Low
$25.08
$73.16
52 Week High
$66.81
$163.71

Technical Indicators

Market Signals
Indicator
CNC
GKOS
Relative Strength Index (RSI) 57.92 74.84
Support Level $38.58 $115.07
Resistance Level $40.15 $118.17
Average True Range (ATR) 1.26 3.10
MACD -0.06 0.01
Stochastic Oscillator 58.80 87.55

Price Performance

Historical Comparison
CNC
GKOS

About CNC Centene Corporation

Centene is a managed care organization that focuses on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges. Centene served 22 million medical members as of December 2024, mostly in Medicaid (about 60% of membership), the individual exchanges (about 20%), and Medicare (about 5%). The company also has a military contract and provides Medicare Part D pharmaceutical plans.

About GKOS Glaukos Corporation

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

Share on Social Networks: